Barclays PLC Makes New $311,000 Investment in Guardian Pharmacy Services, Inc. (NYSE:GRDN)

Barclays PLC purchased a new stake in shares of Guardian Pharmacy Services, Inc. (NYSE:GRDN) in the third quarter, according to its most recent filing with the SEC. The firm purchased 18,500 shares of the company’s stock, valued at approximately $311,000.

Several other institutional investors have also modified their holdings of GRDN. Stephens Inc. AR purchased a new stake in Guardian Pharmacy Services during the third quarter worth $189,000. Point72 DIFC Ltd purchased a new stake in shares of Guardian Pharmacy Services in the 3rd quarter worth about $573,000. Royce & Associates LP acquired a new stake in Guardian Pharmacy Services in the 3rd quarter valued at about $1,260,000. Foundry Partners LLC purchased a new position in Guardian Pharmacy Services during the 3rd quarter valued at about $1,680,000. Finally, Seven Grand Managers LLC purchased a new stake in shares of Guardian Pharmacy Services in the third quarter valued at about $2,515,000.

Insider Buying and Selling

In related news, Director Steven D. Cosler purchased 7,000 shares of Guardian Pharmacy Services stock in a transaction that occurred on Tuesday, November 19th. The shares were purchased at an average cost of $21.22 per share, with a total value of $148,540.00. Following the transaction, the director now owns 17,713 shares of the company’s stock, valued at approximately $375,869.86. The trade was a 65.34 % increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this link.

Guardian Pharmacy Services Stock Performance

Shares of GRDN stock opened at $19.79 on Friday. The business’s 50-day moving average is $21.93. Guardian Pharmacy Services, Inc. has a 1-year low of $14.16 and a 1-year high of $25.74.

Guardian Pharmacy Services (NYSE:GRDN) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($2.00) earnings per share for the quarter, missing analysts’ consensus estimates of $0.19 by ($2.19). The business had revenue of $314.39 million for the quarter, compared to the consensus estimate of $303.21 million. Analysts forecast that Guardian Pharmacy Services, Inc. will post 0.87 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts recently issued reports on GRDN shares. Stephens assumed coverage on Guardian Pharmacy Services in a research report on Tuesday, October 22nd. They set an “overweight” rating and a $21.00 price objective for the company. Truist Financial upped their price objective on Guardian Pharmacy Services from $22.00 to $24.00 and gave the company a “buy” rating in a research report on Friday, November 15th. Finally, Raymond James started coverage on Guardian Pharmacy Services in a research report on Monday, October 21st. They set an “outperform” rating and a $21.00 price objective for the company.

Guardian Pharmacy Services Profile

Guardian Pharmacy Services, Inc, a pharmacy service company, provides a suite of technology-enabled services designed to help residents of long-term health care facilities (LTCFs) in the United States. Its individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities and behavioral health facilities and group homes.